

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Sarilumab for previously treated moderate to severe active rheumatoid arthritis [ID994]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Sanofi (sarilumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Arthritis Action • Arthritis & Musculoskeletal Alliance • Arthritis Care • BackCare • Disability Rights UK • Leonard Cheshire Disability • Muslim Council of Britain • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Pain Society • British Society for Rheumatology • British Society of Rehabilitation Medicine • Physiotherapy Pain Association • Primary Care Rheumatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (adalimumab) • Accord Healthcare (methotrexate) • Amdipharm Mercury (methotrexate) • Biogen Idec (etanercept biosimilar, infliximab biosimilar) • Bristol-Myers Squibb (abatacept) • Concordia International Rx (methotrexate) • Celltrion Healthcare (rituximab biosimilar) • Hameln pharmaceuticals (methotrexate) • Hospira (infliximab biosimilar, methotrexate) • Medac (methotrexate, leflunomide) • Merck Sharp & Dohme (golimumab, infliximab)

National Institute for Health and Care Excellence

Matrix for the technology appraisal of sarilumab for previously treated moderate to severe active rheumatoid arthritis [ID994]

Issue date: March 2017

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS North Durham CCG • NHS Stockport CCG • Welsh Government 	<ul style="list-style-type: none"> • Napp (infliximab biosimilar) • Orion Pharma (methotrexate) • Pfizer (etanercept, methotrexate, sulfasalazine) • Roche (rituximab, tocilizumab) • Rosemont Pharmaceuticals (methotrexate, sulfasalazine) • Sandoz (leflunomide, methotrexate) • <u>Sanofi (leflunomide)</u> • UCB Pharma Limited (certolizumab pegol) • Zentiva (leflunomide) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Arthritis Research UK • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.